Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) – Stock analysts at William Blair upped their FY2017 earnings per share estimates for shares of Biohaven Pharmaceutical in a research note issued on Thursday, according to Zacks Investment Research. William Blair analyst T. Lugo now forecasts that the company will post earnings of ($6.40) per share for the year, up from their previous estimate of ($6.97). William Blair has a “Outperform” rating on the stock. William Blair also issued estimates for Biohaven Pharmaceutical’s Q4 2017 earnings at ($1.69) EPS, FY2018 earnings at ($5.36) EPS, FY2019 earnings at ($5.41) EPS and FY2020 earnings at ($3.22) EPS.
BHVN has been the topic of several other research reports. Morgan Stanley restated an “overweight” rating and set a $38.00 target price (down previously from $47.00) on shares of Biohaven Pharmaceutical in a research report on Tuesday, October 3rd. Zacks Investment Research upgraded Biohaven Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Friday, September 8th. Needham & Company LLC reiterated a “buy” rating and issued a $43.00 price target (up previously from $30.00) on shares of Biohaven Pharmaceutical in a report on Wednesday, September 13th. BidaskClub lowered Biohaven Pharmaceutical from a “hold” rating to a “sell” rating in a report on Friday, October 27th. Finally, Piper Jaffray Companies reiterated a “buy” rating and issued a $54.00 price target on shares of Biohaven Pharmaceutical in a report on Tuesday, September 12th. One analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. Biohaven Pharmaceutical presently has a consensus rating of “Buy” and an average price target of $38.17.
Shares of Biohaven Pharmaceutical (NYSE BHVN) traded down $0.08 during trading on Monday, hitting $21.10. The company had a trading volume of 532,300 shares, compared to its average volume of 216,377. Biohaven Pharmaceutical has a 52 week low of $17.00 and a 52 week high of $39.51.
In other news, insider John Tilton sold 30,000 shares of the stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $29.25, for a total value of $877,500.00. Following the completion of the sale, the insider now directly owns 30,000 shares of the company’s stock, valued at $877,500. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Kimberly Gentile sold 5,000 shares of the stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $29.28, for a total value of $146,400.00. Following the completion of the sale, the vice president now directly owns 5,000 shares of the company’s stock, valued at $146,400. The disclosure for this sale can be found here. In the last quarter, insiders sold 439,131 shares of company stock worth $12,011,701.
Several institutional investors have recently modified their holdings of BHVN. Legal & General Group Plc purchased a new stake in shares of Biohaven Pharmaceutical in the third quarter worth approximately $119,000. Nationwide Fund Advisors purchased a new stake in shares of Biohaven Pharmaceutical in the third quarter worth approximately $214,000. American International Group Inc. purchased a new stake in shares of Biohaven Pharmaceutical during the third quarter valued at approximately $251,000. State of Wisconsin Investment Board purchased a new stake in shares of Biohaven Pharmaceutical during the third quarter valued at approximately $262,000. Finally, Susquehanna International Group LLP purchased a new stake in shares of Biohaven Pharmaceutical during the third quarter valued at approximately $302,000. 47.76% of the stock is owned by hedge funds and other institutional investors.
WARNING: This piece of content was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of international trademark and copyright laws. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2017/12/05/william-blair-research-analysts-lift-earnings-estimates-for-biohaven-pharm-bhvn.html.
Biohaven Pharmaceutical Company Profile
Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.
Get a free copy of the Zacks research report on Biohaven Pharmaceutical (BHVN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Biohaven Pharmaceutical Holding Co Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical Holding Co Ltd and related companies with MarketBeat.com's FREE daily email newsletter.